The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Transactions / E••••••• C••••••••• G••••• I•••

G•••• P•••• Partners Completes Investment in E••••••• C••••••••• Group to Fund Accelerated Growth - G•••• P•••• Partners

Platform acquisitionclosedannounced Jul 21, 2022closed Jul 21, 2022Fact
What happened
Platform
not an add-on on record
Control
Control
Share acquired
unknown
Industry
business_services / consulting
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
5 named
Buy side
  • R•••• S•••••Deal partnerconfirmed
    Sophisticated data analysis is critical to clinical trial and regulatory success and pharma companies rely on specialized CROs like E••••••• for outsourced biostatistics support,” said R•••• S•••••, Managing Director at G•••• P•••• Partners.
  • Form ADV reports 'G•• I•• • E•••••••• L••' (first reported 2023-03-31) under the sponsor, named for E••••••• C••••••••• G••••• I•••
  • G•••• P•••• Partners Completes Investment in E••••••• C••••••••• Group to Fund Accelerated Growth - G•••• P•••• Partners | published on G•••• P•••• Partners's own news page www.gppfunds.com
Side not stated
  • “G•••• P••••’s expertise and investment success in the pharmaceutical services space was clearly evident when they first approached us about a partnership,” said G••••• G••••, CEO of E•••••••.
  • G•••• P•••• Partners Completes Investment in E••••••• C••••••••• Group to Fund Accelerated Growth - G•••• P•••• Partners
Evidence
G•••• P•••• Partners Completes Investment in E••••••• C••••••••• Group to Fund Accelerated Growth - G•••• P•••• Partners
G•••• P•••• Partners Completes Investment in E••••••• C••••••••• Group to Fund Accelerated | Private Equity Intelligence | DFX